Business Context and Reporting Period
This Form 8-K Current Report was filed by McKesson Corporation on July 25, 2018, with the earliest event reported on July 31, 2018. The filing primarily addresses significant changes in executive leadership and corporate governance bylaws.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses on personnel and governance rather than financial performance data.
Material Changes
- Executive Appointment: Brian S. Tyler was appointed as President and Chief Operating Officer, effective August 2, 2018. He previously served as Chairman of the Management Board of McKesson Europe AG.
- Executive Departure: Nick Loporcaro, President of McKesson U.S. Pharmaceutical and Specialty Health, announced his departure to pursue other opportunities.
- Bylaw Amendments: The Board approved amendments to the Amended and Restated By-Laws, effective August 2, 2018, to clarify that the CEO and President may be separate persons and to define their respective roles and authorities.
Compensation and Governance Details
In connection with his appointment, Brian S. Tyler's compensation package was approved by the Compensation Committee, effective August 2, 2018:
- Base Salary: Increased to $1,000,000 annually.
- Target Annual Bonus: Increased to 125% of salary under the Management Incentive Plan.
- Long-Term Incentives: Target cash award increased to $800,000; Performance Stock Unit target award of $500,000 for the FY 2019–FY 2021 period; Stock option grant with a value of $300,000.
- Benefits: Eligible for executive physicals, severance policy, and Change in Control Policy (Tier One).
Until a replacement is named for Nick Loporcaro, Brian S. Tyler will lead the U.S. Pharmaceutical and Specialty Health businesses directly.
Investor Verification Checklist
- Verify the effective date of the By-Law amendments (August 2, 2018) and review Exhibit 3.2 for full text.
- Confirm the transition timeline for the U.S. Pharmaceutical and Specialty Health leadership following Nick Loporcaro's departure.
- Review the 2018 Annual Proxy Statement (filed June 15, 2018) for detailed descriptions of the compensation plans referenced in this filing.
- Monitor future filings for the appointment of a successor to Nick Loporcaro.